Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 5/20 | 0.66 |
| ▸ | DRD3 | P35462 | 5/20 | 0.66 |
| ▸ | DRD4 | P21917 | 4/20 | 0.66 |
| ▸ | DRD2 | P14416 | 4/20 | 0.66 |
| ▸ | DRD5 | P21918 | 3/20 | 0.66 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193190 | 0.87 | DRD1 (0.70) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL18723736 | 0.85 | DRD3 (0.50) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL741396 | 0.83 | DRD1 (0.68) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL11923826 | 0.80 | — | — | |
| SCHEMBL22788528 | 0.76 | CYP2C19 (0.48) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL11982480 | 0.75 | DRD1 (0.47) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL22593357 | 0.75 | PNMT (0.45) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL17461324 | 0.75 | DRD1 (0.44) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL18884388 | 0.75 | DRD1 (0.47) | DRD1DRD3DRD4DRD2DRD5 | |
| SCHEMBL8142884 | 0.75 | CYP2C19 (0.44) | DRD1DRD3DRD4DRD2DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | claimed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| WO-2025045145-A1 | WRN HELICASE-INHIBITING BIS-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 广州科恩泰生物医药科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119528909-A | Bisheterocyclic derivative for inhibiting WRN helicase, pharmaceutical composition containing bisheterocyclic derivative and application of bisheterocyclic derivative | 上海科恩泰生物医药科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
| EP-4159736-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Longwood Biopharmaceuticals Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023036140-A1 | 3CLPRO PROTEASE INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-03-16 | — | — | WO | disclosed |
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | RATIOPHARM GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | CADILA HEALTHCARE LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | CADILA HEALTHCARE LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| WO-2007042912-A2 | HETEROCYCLIC COMPOUNDS AS PSTAT3/IL-6 INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-19 | — | — | WO | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | IL6, IL6ST, STAT3 | DRD1 4832/4885DRD3 4845/4885DRD4 4860/4885 |
| US-20070105847-A1 | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | GPR119, PPARG, FABP4 | DRD1 2324/4885DRD3 2164/4885DRD4 2682/4885 |
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | CYP2C19, ADH1C, TBXA2R | DRD1 859/4885DRD3 722/4885DRD4 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.